Cost Effectiveness Analysis of A Device to Monitor Levodopa-Induced Dyskinesia In Parkinson's Patients.

CONTACT US 1. http://www.parkinsons.org.uk/content/what-parkinsons. Accessed August 2015. 2. Cancela J, Arredondo MT, Hurtado O. Guidelines for the economic analysis of a telemetic platform for Parkinson's disease monitoring. BIBE. 2013: page 1-4. IEEE. 3. Wood et al. Incidence and predication of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002; 72: 721-725. 4. Haycox, A, Armand C, Murteira S, Cochran J, Francois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009: 26; 791-801. REFERENCES Patients with Parkinson’s disease (PD) are frequently treated with levodopa which helps to reduce stiffness, slowness and tremors. Many patients develop problems with involuntary movements called ‘dyskinesia’ as a result of levodopa medication. Levodopa-induced dyskinesia (LID) can be improved by adjusting the dosage to find a tolerable balance between the benefits and side effects. These movements fluctuate in severity throughout the day but there is no reliable way of objectively monitoring them at home. This means that clinicians have very scant clinical information to base treatment decisions on, resulting in a series of ‘trial and error’ drug regimen changes, and delayed optimal management.